Navigation Links
Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference
Date:9/9/2011

order Multisite dressing.  Its imaginative shape is designed to fit the unique contours of the body, and stay in place.  ALLEVYN Multisite, along with ALLEVYN Gentle Border Sacrum and ALLEVYN Gentle Border Heel are uniquely shaped dressings that form the foundation for the new 'Human Shaped Wound Care' campaign.  As part of the campaign introduction, Smith & Nephew will be hosting an interactive ALLEVYN Gentle Border Multisite Challenge, at their booth (#225).

"Reducing the human and economic cost of wounds is a core value of Smith & Nephew.  We are focused on innovation and best practice techniques for the prevention and healing of wounds. Imaginative solutions like our new Human Shaped ALLEVYN dressings help improve outcomes for patients and at the same time conserve resources for health care systems," said Thomas J. Dugan, President of Smith & Nephew's North American Advanced Wound Management Division.

Additionally, Smith & Nephew will be offering Twin Towers Pins to attendees, for a $2 donation to the Twin Tower Orphan fund. The program was founded on September 11, 2001 with the sole purpose of providing educational and welfare assistance to the children who lost parents by the terrorist attacks on 9/11.

Smith & Nephew will continue its presence at tradeshows throughout the fall at:

  • Diabetic Limb Salvage conference (Sept. 22-24)
  • The American Society of Plastic Surgeons meeting (Sept. 23-27)
  • The Symposium of Advanced Wound Care (Oct. 13-15)
  • The Orthopedic Trauma Association annual meeting (Oct. 12-15)
  • Health Industry Distributers Association Conference & expo (Oct. 19-21)
  • The Canadian Association of Wound Care annual conference (Nov. 3-6).

To get the latest and timeliest news from the Advanced Wound Management division of Smith & Nephew, r
'/>"/>

SOURCE Advanced Wound Management division of Smith & Nephew
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
8. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
9. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... LEIDEN, Netherlands, March 8, 2011 Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) today announced that ... Subsequent Offering Period), Johnson & Johnson has acquired 98.89% ... treasury shares held by Crucell) and 98.93% of the issued ...
... 2011 Sequenom, Inc. (Nasdaq: SQNM ) today ... year ended December 31, 2010. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ... Total revenue for the fourth quarter of 2010 grew 28% ... quarter of 2009. The increase in revenue compared to the ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 2Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 3Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 4Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 5Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 6Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 8Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 9
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... ... Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. Collazo, ... Collazo, a 15 year veteran of helping drug, biologic and device firms reduce ...
(Date:7/30/2015)... ... 30, 2015 , ... World Patent Marketing, a vertically integrated ... that can help people during emergencies. , "The worldwide mobile health market revenue ... of World Patent Marketing. "Currently, there are about 97,000 mobile health apps available ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by ... , The decision will also allow him to spend more time in the office ... admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... most common cancers in the world. Although the prognosis ... survival rate for those who receive operative treatment is ... surgical intervention. However, many surviving patients might suffer from ... in their later life. , A research article ...
... agent for treatment of patients with chronic hepatitis ... monotherapy leads to the emergence of lamivudine-resistant hepatitis ... infected with HBV. Sensitive methods for early detection ... decisions in treating patients with HBV infection. , ...
... no shortages here , , WEDNESDAY, Jan. 16 (HealthDay News) ... the safety gaps in the U.S. food system. , ... one federal "superagency" to monitor food safety; beefing up ... the very least, giving the FDA the ability to ...
... builds on success in Eastern Washington, SPOKANE, Wash., ... establishing a larger presence in the Spokane community.,The new ... are already employed by WDS in Spokane. Eventually, the ... tremendous success with our customer service center in,Colville and ...
... Dr. Judah,Folkman, founder of the field of angiogenesis, died ... one of the thousands of lectures,that he gave to ... Folkman was founder and director of the Vascular Biology,Program ... Surgery,and Cell Biology at Harvard Medical School., When ...
... Expected Recurring ... ... Rate ... Stereotaxis, Inc. (Nasdaq:,STXS) today reported that due to the previously delayed European launch of,its partnered ...
Cached Medicine News:Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2Health News:U.S. Food Safety: Solutions at a Glance 2Health News:U.S. Food Safety: Solutions at a Glance 3Health News:Washington Dental Service Opens Larger Spokane Office 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 3Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 4Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 2Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 3Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 4
An Antiseptic - Antibacterial Cleanser that helps reduce bacteria that can potentially cause disease.Does not produce the systemic adverse effects associated with iodine or iodine by-products and is ...
... for professional degerming, pre-op and post-op ... combining quaternary and substituted phenolic active ... emollients and surfactants. Unprecedented efficacy on ... in 30 seconds. Techni-Care represents a ...
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... pouches are designed for individual application and ... used in nursing homes, home healthcare settings, ... other hospital departments. This unit dose pouch ... antiseptic, germicidal and cleansing agent. Hydrogen Peroxide's ...
Medicine Products: